Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...
Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...
Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...
Chronic kidney disease can progress for years without obvious symptoms, making routine screening during annual checkups ...
Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...
Tekeya Bodie has days when she cries and asks God, why her? She also has days when she feels like she is getting back to some ...
As it was showcased in the first half against the Cleveland Cavaliers, there's one specific way to make the Tyler ...
The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...
The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results